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€-1335.30, the largest difference was due to the length
of hospital stay (€-1468.50). The surgical procedure was
the only item that resulted in more resource consumption
in the TVT procedure (differential cost per patient of
€158.29). Sensitivity analyses showed that even in the
case where the TVT patients are hospitalized for 3 days,
the TVT procedure remains the least resource consuming
and the least costly option (differential cost per patient of
€-513.80). CONCLUSIONS: The TVT procedure proved
to be more efﬁcient than the OBC option in the surgical
treatment of female SUI.
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OBJECTIVE: This analysis addresses the cost-
effectiveness of the new extended release formulation
(XL) of Ditropan (oxybutynin) for the treatment of over-
active bladder relative to immediate release Detrol
(tolterodine), if the drugs are priced equivalently.
METHODS: A state-transition model was developed to
compare health economic outcomes over the course of
one year. Effectiveness and treatment persistence data
were derived from the OBJECT trial, a 3-month ran-
domized, double-blind study comparing Ditropan XL 10
mg with Detrol 4mg and used, together with data from
the literature to project outcomes beyond the trial time.
Severity-speciﬁc cost proﬁles for incontinence were devel-
oped for the province of Ontario, and are reported in
2002 Canadian dollars. In the principal analyses, only
direct costs were included and were limited to drug price,
physician visits, and pad or protection usage. RESULTS:
Ditropan XL is predicted to be the dominant therapeutic
option, with higher effectiveness and lower overall costs
than Detrol. After 1 year, total costs are expected to be
an average of $32 lower per patient with Ditropan XL,
while 3.15 more patients per 100 treated attain complete
continence (20.4% versus 17.2%). As well, more patients
treated with Ditropan XL have less than 7 incontinent
episodes per week. Over the course of the year, patients
on Ditropan XL are expected to have an average of 16
additional incontinence-free days. Results are most sensi-
tive to relative drug prices, with a price differential of only
$0.11 per day required for savings with Ditropan XL to
be eliminated. In other sensitivity analyses, however,
Ditropan XL maintained its advantage over wide ranges
of inputs. CONCLUSION: These analyses suggest that,
at price parity, Ditropan XL provides better results than
Detrol over 1 year and reduces costs.
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OBJECTIVES: The safety and efﬁcacy of Renagel® (seve-
lamer hydrochloride) in binding phosphate in patients
with end stage renal disease and its ability to attenuate
the progression of cardiac calciﬁcation has been well doc-
umented but not the longer-term health and economic
consequences. Thus, a model of the predicted long-
term consequences of Renagel® compared to calcium-
based binders (acetate and carbonate) was developed.
METHODS: Long-term cardiovascular implications of
one year of treatment with phosphate binders in patients
on hemodialysis are estimated based on the patient’s
demographics, co-morbidities, and physiologic and renal
parameters. The initial calciﬁcation score and expected
changes over one year are derived using regression equa-
tions developed from the Treat-to-Goal study and trans-
lated to cardiovascular disease risk based on equations
developed from a long-term cohort study (London). The
implications of cardiovascular disease for life expectancy
and medical costs are accounted for from a US payer per-
spective. RESULTS: In a population of 100 patients, the
cardio-protective effect of Renagel® over 1 year is esti-
mated to prevent 9 future cardiovascular events and to
save 18 life years compared with calcium acetate; and 10
events and 18 life years compared to carbonate. These
events would cost $205,600 and $226,700 to manage.
These beneﬁts are obtained at a net cost of about $37,900
and $19,500, respectively. The incremental cost-
effectiveness ratios amount to $2200 and $1100 per 
(discounted) life year gained; and $4400 and $2300 per
cardiovascular event prevented. CONCLUSIONS: Wide-
spread use of Renagel® for treatment of hyperphos-
phatemia in patients on hemodialysis may seem like just
another burden on already strained health care resources.
In the context of dialysis, at a median cost-effectiveness
ratio of $46,000 per life year gained, the results of this
study provide evidence that such intervention would be
economically sound.
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OBJECTIVES: Lower urinary tract symptoms (LUTS)
such as detrusor instability or urinary retention strongly
impacts quality of life, involving economical aspects and
social living. The aim of our investigation is to record
changes in hospitalizations, Urological, and general prac-
titioner visits before and after sacral nerve stimulation
therapy. Expenses for pads, catheters, and drugs are also
investigated. METHODS: From February 2000 to Sep-
tember 2002 we enrolled 62 patients in the economic
session of the Italian Sacral Nerve Modulation Registry
(mean age 50 years old, from 22 to 70). Economic data
was recorded in order to compare costs with clinical
results of sacral nerve modulation therapy in patients
with LUTS. In this group 41 were incontinent patients
(61% female) mean age 53; 21 patients (71% female)
mean age 46 had urinary retention. RESULTS: We per-
formed a quarterly analysis, comparing the baseline data
to the last follow up available (12 month). Visits to the
general practitioner decreased from 1.1 to 0.05 (p < 0.01),
visits to the urologist did not change signiﬁcantly from
baseline (1.5 to 1.2). Diagnostic tests decreased from 2 to
0.8 (p < 0.01). In the use of pads we observed a major
change from 2.1/day (3 months expenses per patient of
€120.96) to 0.5 (3 months expenses per patient of €28.8)
(p = 0.08); For urinary retention the use of catheters
decreased from 1.1 baseline (3 months expenses per
patient of €178.2) to 0.1 at 12 months (3 months
expenses per patient of €16.2) (p = 0.09). Drug con-
sumption decreased signiﬁcantly (p < 0.05) from €47.24
to €10.53. CONCLUSIONS: The reduction in daily con-
sumption of pads and catheters (which is the major cost-
driver of urinary disorders), but also the reduction of
costs due to general practitioner visits, diagnostic tests,
and drug consumption are signiﬁcantly changed.
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OBJECTIVES: An important complication of Benign
Prostate Hyperplasia, a bothersome condition of ageing
men, is Acute Urinary Retention (AUR). This condition
needs acute catheterisation and is a predisposing factor
for surgery. Removal of the catheter is only possible in a
minority of patients if no drugs are used. Alpha-blockers
may increase the success rate of removing the catheter and
decrease the need for future surgery. This study assessed
the costs of treating patients with AUR with alfuzosin,
watchful waiting or immediate prostatectomy in Belgium.
METHODS: According to a randomised controlled trial
(ALFAUR study) removing the catheter is successful in
47.9% of patients treated with watchful waiting and
61.9% of those treated with 3 days of alfuzosin (cost
€0.92 per day). Based on the treatment path and imme-
diate clinical outcome in the ALFAUR study, a medical
decision model to compare the costs and health effects of
the three possible strategies was built in Excel MS 2000,
whereby follow-up results were obtained from epidemio-
logical data. The cost of events was based on a patient
chart review (n = 63) in patients with a ﬁrst episode of
AUR and conducted from the health care payer’s per-
spective. The time horizon of the model was 6 months.
RESULTS: At 6 months, 32.3% of patients who initially
voided successfully were re-hospitalised to undergo a
prostatectomy. Six-month cost of patients treated with
alfuzosin, watchful waiting and immediate prostatectomy
were respectively €4175, €4758, and €6036. These results
were robust under a wide range of plausible assumptions.
CONCLUSIONS: Based on the current available clinical
data, a very small investment (3 units of alfuzosin) can
lead to important savings for the public health care payer
by treating all patients hospitalised with AUR with alfu-
zosin. Further research on utilities in these patients is
expected to strengthen this conclusion.
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AVF are recommended over catheters because they have
lower morbidity and costs. OBJECTIVES: The aim was
to evaluate the cost effectiveness according to patient’s
survival and the difference caused by the delay of an ade-
quate AVF implementation when starting periodical
haemodialysis PHD. Pts included: all pts but 19pts start-
ing PHD during 1996–2000 (n = 133). One deﬁned three
groups of pts according to the time in having deﬁnitive
AVF: Group 1 (G1) having an adequate functioning AVF
before initiating PHD and it lasting at least three months
(53%); G2 not having a AVF at the beginning of PHD,
but in the ﬁrst 3 months of the entrance in PHD (25%)
and G3 being using catheters for more than 3 months
(22%). Studied resources cost: the AVF execution and
patient’s medical care, the mean hospital admissions (HA)
and their mean length stay (LS), catheter cost and time of
personnel as direct and indirect costs. Beneﬁts were cal-
culated evaluating patient’s survival and drugs were not
included by the complexity and patient’s diversity.
RESULTS: G1 were younger than G2 and G3, had lower
infections and less attributable death, lower CI, less HA
and LS. Total AVF costs were estimated in €3071. It could
have been avoided about 11–15% because of catheter
infections and 12 attributed deaths. So mean beneﬁts
could have been €5400 respect to G2 and €6860 to G3.
